Analysts have been eager to weigh in on the Healthcare sector with new ratings on Phathom Pharmaceuticals (PHAT – Research Report) and Omeros (OMER – Research Report).
Phathom Pharmaceuticals (PHAT)
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals today and set a price target of $55.00. The company’s shares closed last Monday at $26.25.
According to TipRanks.com, Stringer has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Phathom Pharmaceuticals is a Moderate Buy with an average price target of $56.50.
See Insiders’ Hot Stocks on TipRanks >>
Omeros (OMER)
In a report released today, Serge Belanger from Needham maintained a Hold rating on Omeros. The company’s shares closed last Monday at $6.00.
According to TipRanks.com, Belanger is a 3-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Omeros with a $12.33 average price target, implying a 101.5% upside from current levels. In a report issued on October 4, Maxim Group also downgraded the stock to Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PHAT:
